【导读】超5万个中成药批准文号面临合规大考，头部企业已提前布局，产业集中度加速提升 "公司主要中药品种的说明书均已修订完善，并完成了再注册。"2026年2月5日，桂林三金（002275）在投资者关系平台上如此回复投资者关切的询问。就 在前一天，以岭药业（002603）也明确表示，公司17个专利中药新药的说明书"三项均有明确表述，符合相关规定。" "截至2025年末，公司原有的104个生产批文已全部完成药品再注册，核心产品龟龄集的说明书也已修订获批，明确表示不存在因新规退市的风险。"广誉 远（600771）也在互动平台回答投资者提问时表示。 国家药监局2023年发布的《中药注册管理专门规定》第七十五条要求：2026年7月1日起，中药说明书【不良反应】【禁忌】【注意事项】中任何一项仍标 注"尚不明确"的，将不予再注册。 大批中成药将退市？存在"误读" "大批中成药将退出市场"的相关话题一度登上热搜，A股投资者也密集在互动平台发问，关心"三年窗口期"即将关闭，是否会影响相关公司的药品销售。 东阿阿胶（000423）也告诉记者，复方阿胶浆（有糖/无糖），已于2025年进行说明书安全性信息修订，并于2026年1月7日正 ...

Core Viewpoint - Guangyuyuan (600771) emphasizes that its product, Gui Ling Ji, is a prescription drug under the National Medicine Standard and should be used under professional medical guidance [1] Group 1: Product Information - Gui Ling Ji is indicated for "strengthening the body and brain, tonifying the kidney and qi, and enhancing appetite" [1] - The product is based on traditional Chinese medicine theory, which associates nasal inflammation with qi deficiency, suggesting that Gui Ling Ji may improve this condition by tonifying kidney qi to enhance lung qi [1] Group 2: Usage Recommendations - The company advises consulting a professional physician for personalized medication plans based on individual health conditions and historical usage records of Gui Ling Ji [1] - It is recommended to consider seasonal characteristics when formulating a personalized medication strategy to ensure safe and effective use [1]

Core Viewpoint - Shanxi province, known for its traditional Chinese medicine ("Jin Medicine"), is focusing on high-quality development of the Chinese herbal medicine industry through standardized production and sales systems, diversified value systems, efficient innovation systems, and comprehensive support systems [1][2]. Group 1: Industry Development - The scale of Shanxi's Chinese herbal medicine industry is expanding, with continuous optimization of structural layout and gradual emergence of competitive advantages [1]. - Challenges include mismatches between industry development and resource endowments, as well as non-unified quality standards in planting and processing [1]. - There is an urgent need to enhance technological innovation capabilities, extend the industrial chain, and improve operational support systems [1]. Group 2: Recommendations for Improvement - Suggestions include implementing full-cycle management by focusing on seed quality, promoting ecological planting, enhancing product value, ensuring quality safety, and strengthening trading platforms [1]. - To extend the industrial chain and build a diversified value system, it is recommended to strengthen the Chinese medicine manufacturing industry and cultivate large-scale herbal medicine enterprises [1]. - The development of a health lifestyle industry and the integration of tourism with traditional medicine are also proposed to enhance market presence [1]. Group 3: Technological and Educational Enhancements - Emphasis on strengthening technological empowerment and building an efficient innovation system is highlighted [2]. - Recommendations include addressing seed source and cultivation technology challenges, forming research teams to cultivate local varieties, and promoting modern cultivation techniques [1][2]. - The establishment of a provincial Chinese medicine laboratory and the development of proprietary health products are also suggested to enhance clinical treatment capabilities [1]. Group 4: Support Mechanisms - The need for a comprehensive support system is emphasized, including ensuring reasonable returns for growers and increasing research and development subsidies [2]. - The cultivation of professional talent through specialized programs in "Traditional Chinese Clinical Pharmacy" is recommended to foster a new generation of practitioners who understand both medicine and pharmaceuticals [2].

证券日报网讯 2月2日，广誉远在互动平台回答投资者提问时表示，公司独家产品龟龄集合法合规生 产、销售，不存在退市情况。关于2025版《中国药典》不再收录该产品，原因为处方中含穿山甲原料， 在合规管理下，不影响企业生产和患者使用。针对《中药注册管理专门规定》中关于说明书方面的规 定，该规定于2023年2月10日正式颁布之时公司就已积极梳理、研判并全面部署修订工作，截至2025年 年末，公司原有104个生产批文已全部完成药品再注册。龟龄集说明书已完成修订并获批，不存在受新 规影响退市的风险。提示广大投资者审慎辨别网络信息，以国家监管部门官方网站、公司官方信息为 准，注意投资风险。 （文章来源：证券日报） ...

Group 1 - The core point of the article is the appointment of Wang Penghao as the Vice President of Guangyuyuan, which is expected to enhance the company's growth strategy and channel development [1][3][4] - Wang Penghao has over 20 years of experience in the pharmaceutical marketing field, having worked with both foreign and domestic leading pharmaceutical companies, which aligns well with Guangyuyuan's operational needs [2][3] - Guangyuyuan, a time-honored brand in traditional Chinese medicine, has shown solid growth, with a revenue of 1.061 billion yuan in the first three quarters of 2025, marking an 18.71% year-on-year increase [4] Group 2 - The company focuses on three main business segments: traditional Chinese medicine, premium Chinese medicine, and health wine, with notable products including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan [3][4] - The appointment of Wang is seen as a strategic move to adapt to a new growth phase, enhancing brand communication and marketing efficiency [3][4] - Guangyuyuan has a strong foundation for growth, evidenced by a net profit of 78.884 million yuan in the first three quarters of 2025, reflecting an 11.16% year-on-year increase [4]

Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to quality and traditional pharmaceutical practices, ensuring the efficacy of its classic products like Gui Ling Ji and Ding Kun Dan, while maintaining strict adherence to GMP standards in production [1] Group 1: Quality Control - The company views product quality as its core lifeline, implementing a comprehensive quality control system throughout the entire process from raw material procurement to finished product release [1] - Guangyuyuan's commitment to high standards in quality management is reflected in its adherence to traditional pharmaceutical teachings, ensuring that every batch of products is stable and reliable [1] Group 2: Strategic Focus - The company will continue to focus on its "1541" strategic framework, centering on its main responsibilities and core growth objectives, with an emphasis on performance-driven management and sales breakthroughs [1] - Guangyuyuan aims to enhance operational quality while safeguarding consumer rights through its commitment to high-quality product manufacturing [1]

Core Viewpoint - Guangyuyuan (600771) has reported significant achievements in its operational goals for 2025, laying a solid foundation for its 2026 objectives, with a focus on systematic layout, mechanism improvement, channel expansion, operational quality enhancement, and brand building [1] Group 1: Operational Performance - In the first, second, and third quarters of 2025, the company achieved double-digit growth in core indicators [1] - The company became the first in the nation to receive approval for the ancient classic prescription new drug Banxia Xiexin Decoction granules [1] Group 2: Brand Development - The brand's visibility has been enhanced through participation in various media programs, including CCTV's "Health China Says" and "Health China Travels the World," as well as special features like "Time Slows Down with Qihuang" [1] Group 3: Strategic Focus - The company acknowledges the gap between current operational results and market expectations, committing to focus on value growth, core responsibilities, standardized operations, and governance improvement to promote sustainable and healthy development [1]

Core Viewpoint - Guangyuyuan (600771) has introduced various specifications of its proprietary medicine, Gui Ling Ji, based on factors such as efficacy, treatment duration, consumption scenarios, and market demand [1] Product Specifications - The company offers Gui Ling Ji in multiple specifications: 12 capsules, 18 capsules, 24 capsules, 30 capsules, 36 capsules, and 60 capsules [1] - Consumers are encouraged to purchase and use the product according to their needs under the guidance of a physician [1]

Core Viewpoint - The article highlights how Guangyuyuan, a nearly 500-year-old Chinese time-honored brand, continues to thrive by embracing innovation while adhering to traditional practices in the face of industry competition and technological advancements [5]. Group 1: Traditional Practices - Guangyuyuan maintains a commitment to traditional production methods, such as the three-year sun-drying process for vinegar, which ensures the efficacy of its products [6]. - The company has developed unique processing techniques over time, including various methods like steaming, frying, and sun-drying, which are essential for enhancing the medicinal properties of their products [6][7]. - Guangyuyuan is one of the few traditional Chinese medicine companies with uninterrupted inheritance, boasting 20 major intangible cultural heritage projects and 30 inheritors [7]. Group 2: Product Portfolio - The core products of Guangyuyuan, including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan, account for over 90% of the company's total revenue, with most being prescription drugs [7]. - The company has introduced innovative products like the "Youth Cannon" version of Gui Ling Ji, which has seen significant sales growth during promotional events [8]. Group 3: Business Strategy and Growth - In the first three quarters of 2025, Guangyuyuan achieved a revenue of 1.061 billion yuan, marking an 18.71% year-on-year increase, with a profit growth of 31.73% [9]. - The company aims to expand its market presence through the revitalization of traditional products, the development of health products, and strategic marketing initiatives [9][10]. - Guangyuyuan has established a new positioning and mission across its various business segments, focusing on academic standing, high-end health branding, and market scale enhancement [11].

Core Viewpoint - The recent legal victory of Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd. against a health company over trademark rights and unfair competition sets a new benchmark for intellectual property protection in the traditional Chinese medicine industry [1][3]. Group 1: Legal Case Summary - The case lasted for two years and resulted in a significant ruling that not only compensated Guangyuyuan for economic losses but also enhanced its brand reputation [1][2]. - The court recognized the "Guangyuyuan" trademark as a well-known trademark, confirming that the defendant's use of the name caused consumer confusion and constituted unfair competition [3]. - The compensation amount was doubled from 500,000 yuan to 1 million yuan, and the defendant was ordered to cease sales of infringing products in mainland China [3]. Group 2: Industry Context - The number of disputes involving time-honored brands has been increasing, with nearly 50% of such cases involving trademark imitation or malicious registration [1][4]. - The protection of traditional brands is supported by national policies, such as the "Intellectual Property Power Construction Outline (2021-2035)" which emphasizes the development and protection of traditional brands [2][4]. - The case highlights the challenges faced by traditional brands in protecting their intellectual property, including difficulties in evidence collection and high litigation costs [4]. Group 3: Company Performance - Guangyuyuan has seen a turnaround in its financial performance, with revenue exceeding 779 million yuan and net profit reaching approximately 76.86 million yuan in the first half of the year, marking a significant improvement [5]. - The company’s traditional production techniques have been recognized as national intangible cultural heritage, contributing to its brand value and market position [5]. - The company has initiated a "1541" development strategy to adapt to new industry dynamics and ensure sustainable growth [5].